Madrigal Pharmaceuticals
MDGL on XNAS, Madrigal Pharmaceuticals, Inc.
Measures activity, not value. Not investment advice.
Latest quarter (Jul 2026)
+50%
-160.6 pts vs its 3-year median
Sharp changes
6
quarterly revenue change, quarterly capital spending jump
What usually follows Revenue growth was not followed by a clear share-price difference over the next 6 months. No relationship found How we measured it
10-Q and 10-K figures, by the quarter they describe. Dashed: 3-year median.
See the numbers
| Quarter of Jul 2026: +50% |
| Quarter of Apr 2026: +71% |
| Quarter of Jan 2026: +127% |
| Quarter of Oct 2025: +211% |
| Quarter of Jul 2025: +362% |
| Quarter of Apr 2025: +1354% |
What the numbers say
- Median revenue growth on a year earlier: +50% in the quarter from 1 Jul 2026 (3-year median +211%).
- 6 sharp changes in all loaded history (quarterly revenue change, quarterly capital spending jump).
- Median growth on a year earlier, latest complete quarter: the largest is Inventory, +77%.
See the numbers
| Inventory | +77% |
| R&D expense | -59% |
| Revenue | +50% |
Every measure from this source
5 years, by the period each figure describes
Sharp changes
6 in all loaded history, strongest first
Madrigal Pharmaceuticals reported revenue of $212.8M for the quarter ended 30 Jun 2025, 15× the same quarter last year.
Same quarter last year: $14.6M; its normal quarter is $7.3M.
See the evidence
- This period
- $212.8M (the quarter ended 30 Jun 2025)
- Normal quarter (median of 8 earlier)
- $7.3M
- Typical spread (median absolute deviation)
- $7.3M
- How far from its usual level
- +18.9
- Same quarter last year
- $14.6M
- History used
- 2,648 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Madrigal Pharmaceuticals reported revenue of $137.2M for the quarter ended 31 Mar 2025, against none in the same quarter last year.
See the evidence
- This period
- $137.2M (the quarter ended 31 Mar 2025)
- Normal quarter (median of 8 earlier)
- $0
- Typical spread (median absolute deviation)
- $0
- How far from its usual level
- +137.2
- Same quarter last year
- $0
- History used
- 2,557 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Madrigal Pharmaceuticals reported revenue of $103.3M for the quarter ended 31 Dec 2024, against none in the same quarter last year.
See the evidence
- This period
- $103.3M (the quarter ended 31 Dec 2024)
- Normal quarter (median of 8 earlier)
- $0
- Typical spread (median absolute deviation)
- $0
- How far from its usual level
- +103.3
- Same quarter last year
- $0
- History used
- 2,467 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Madrigal Pharmaceuticals reported revenue of $62.2M for the quarter ended 30 Sep 2024, against none in the same quarter last year.
See the evidence
- This period
- $62.2M (the quarter ended 30 Sep 2024)
- Normal quarter (median of 8 earlier)
- $0
- Typical spread (median absolute deviation)
- $0
- How far from its usual level
- +62.2
- Same quarter last year
- $0
- History used
- 2,375 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Madrigal Pharmaceuticals reported revenue of $14.6M for the quarter ended 30 Jun 2024, against none in the same quarter last year.
See the evidence
- This period
- $14.6M (the quarter ended 30 Jun 2024)
- Normal quarter (median of 8 earlier)
- $0
- Typical spread (median absolute deviation)
- $0
- How far from its usual level
- +14.6
- Same quarter last year
- $0
- History used
- 2,283 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
Madrigal Pharmaceuticals reported revenue of $287.3M for the quarter ended 30 Sep 2025, 4.6× the same quarter last year.
Same quarter last year: $62.2M; its normal quarter is $38.4M.
See the evidence
- This period
- $287.3M (the quarter ended 30 Sep 2025)
- Normal quarter (median of 8 earlier)
- $38.4M
- Typical spread (median absolute deviation)
- $38.4M
- How far from its usual level
- +4.4
- Same quarter last year
- $62.2M
- History used
- 2,740 days
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Check it at the source: SEC EDGAR quarterly reports.
The records
One row per company, data through 1 Nov 2026
| Company | Sector | Latest quarter | vs year before |
|---|---|---|---|
| Madrigal Pharmaceuticals | Health Care | $431.3M |